PD‐L1 mAb treatment significantly improved ischemic stroke outcomes, particularly in young mice, by reducing infarct volume, enhancing neurological recovery, and preserving BBB integrity through the upregulation of tight junction proteins, including ZO‐1, Claudin‐5, and Occludin. Here, OCLN is linked to ischemic stroke.